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Abstract
Background: In sub-Saharan Africa (SSA), antiretroviral therapy (ART) can prolong life for HIV-infected patients.
However, patients initiating ART, especially in routine treatment programs, commonly dropout from care either
due to death or loss to follow-up.
Methods: In a cohort of HIV-infected patients initiating ART at a public sector clinic in Uganda, we assessed
predictors of dropout from care (a composite outcome combining death and loss to follow-up). From a large
set of socio-demographic, clinical, and laboratory variables routinely collected at ART initiation, we selected
those predicting dropout at P <0.1 in unadjusted analyses for inclusion into a multivariable proportional hazards
regression model. We then used a stepwise backward selection procedure to identify variables which independently
predicted dropout at P <0.05.
Results: Data from 5,057 patients were analyzed. The median age was 33 years (IQR 28 to 40) and 27.4 %
had CD4+ T-cell counts <100 cells/μL at ART initiation. The median duration of follow-up was 24 months
(IQR = 14 to 42, maximum follow-up = 64 months). Overall dropout was 26.9 % (established cumulative
mortality = 2.3 %, loss to follow-up = 24.6 %), 5.6 % were transferred to other service providers, and 67.5 %
were retained in care. A diagnosis of Kaposi’s sarcoma (hazard ratio (HR) = 3.3, 95 % CI 2.5 to 4.5); HIV-associated
dementia (HR = 2.6, 95 % CI 1.5 to 4.6); history of cryptococcosis (HR = 2.2, 95 % CI 1.4 to 3.3); and reduced hemoglobin
concentration (<11 g/dl versus ≥13.8 g/dl (HR = 1.9, 95 % CI 1.6 to 2.2) were strong predictors of dropout.
Other independent predictors of dropout were: year of ART initiation; weight loss ≥10 %; reduced total
lymphocyte count; chronic diarrhea; male sex; young age (≤28 years); and marital status.
Conclusions: Among HIV-infected patients initiating ART at a public sector clinic in SSA, biological factors
that usually predict death were especially predictive of dropout. As most of the dropouts were lost to follow-up, this
observation suggests that many losses to follow-up may have died. Future studies are needed to identify appropriate
interventions that may improve both individual-level patient outcomes and outcome ascertainment among
HIV-infected ART initiators in this setting.
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Background
Sub-Saharan Africa (SSA) remains the epicenter of the
HIV pandemic. In recent data, the prevalence of HIV in-
fection averaged around 18 % to 26 % in Southern Africa
and 5.1 % to 7.4 % in East Africa [1]. In Uganda, where
HIV prevalence in adults was initially as high as 30 % in
1990 (based on data from antenatal care clinics) [2], ag-
gressive prevention campaigns achieved an initial dra-
matic decline in the prevalence to about 4.1 % at the
end of 2003 [3]. However, recently, the HIV prevalence
has increased again to about 7.4 % in 2013 [2]. Although
HIV incidence appears to be declining in general in SSA
[4, 5], the number of new infections remains high [6].
For the past decade, antiretroviral therapy (ART) has
been rolled out in the region [7]. ART can prolong life
for HIV-infected patients [8], and is also a major oppor-
tunity for HIV prevention since successful treatment of
those already infected can prevent continued HIV trans-
mission [9]. However, significant challenges remain in
the implementation and evaluation of HIV treatment
services in SSA. In particular, among patients initiating
ART, dropout from treatment is common (as high as
30–50 % at 1 year in some programs) [10, 11]. The ma-
jority of dropouts are due to loss to follow-up [12]. High
rates of loss to follow-up are an important threat to the
success of HIV treatment programs; patients that are
lost can interrupt their treatment, resulting in further
disease progression, continued HIV transmission, and
death [13]. Also, high rates of loss to follow-up compli-
cate program evaluation by biasing mortality estimates
[14, 15]. Interventions are thus needed to improve not
only individual-level patient outcomes but also outcome
ascertainment for HIV infected patients initiating ART
in the region.
Dropout from care is especially common for those re-
ceiving ART from routine treatment programs [11]. As
these programs usually collect a relatively large amount
of sociodemographic, clinical, and laboratory data from
patients at ART initiation, we hypothesized that such
data could be used to pre-emptively identify patients at
high risk of dropout, who in turn might benefit from in-
terventions to promote retention. We therefore aimed to
evaluate predictors of dropout from care among HIV-
infected patients initiating ART at a public-sector clinic
in Uganda.
Methods
Study setting, design, and population
We performed a cohort analysis of data from the
electronic database of the Immune Suppression Syn-
drome (ISS) clinic in Mbarara, Uganda. Dropout from
care among patients on ART is common at this clinic
[16, 17]. HIV treatment services, which are free to
patients, are paid for by the President’s Emergency
Fund for AIDS Relief through the US Centers for
Disease Control, the Uganda Ministry of Health, and
the Makerere University-Mbarara University Joint
AIDS Program. We included in this analysis, the data
of patients that were 16 years and older, who initiated
ART between January 2008 and December 2011. We
chose this period so that we would have adequate
baseline and follow-up data available in the electronic
database.
Ethics statement
We used de-identified data that had already been col-
lected for the patients’ clinical care. As it would have
been either inconveniencing to the patients or difficult
to reach them, we did not seek individual-level consent
from patients to use these data. Instead, we planned to
access only de-identified data and sought a waiver on
the requirement for individual-level consent from the
local Institutional Review Board (IRB). This waiver was
granted pre-analysis by the Mbarara University of
Science and Technology Institutional Review Board
(MUST-IRB). The data management committee of the
ISS Clinic also approved the study.
Data collection procedures
Since 2007, clinic data routinely collected by nurses,
counselors, physicians, and pharmacy staff on paper
have been subsequently entered into an electronic data-
base maintained in the Open Medical Records System
[18]. For this analysis, the clinic’s data manager extracted
de-identified patient data on our behalf.
Predictor measurements
We investigated socio-demographic, clinical, and la-
boratory variables that are routinely measured at
ART initiation as predictors of dropout. Socio-
demographic variables included age, sex, education
level, time spent travelling to the clinic, and marital
status. Clinical variables included histories/diagnoses
of opportunistic infections (OIs) and other comorbid-
ities at ART initiation. We assessed only those disor-
ders that are commonly diagnosed in this setting,
and which we expected to be diagnosed with relatively
good specificity. These disorders included: tuberculosis
(TB), Kaposi’s sarcoma (KS), cryptococcosis, esophagitis,
oral candidiasis, chronic diarrhea, HIV-associated demen-
tia, and weight loss ≥10 %.
At this clinic, TB is diagnosed using laboratory
(Ziehl-Neelsen sputum smears), clinical (presence of
chronic productive cough, weight loss, night sweats,
and abnormal chest examination findings), and radio-
logical assessments (abnormal findings on chest radio-
graphs suggestive of TB, e.g., a "miliary" pattern of
small nodules in the lung parenchyma). TB cases are
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defined according to standard criteria [19]; diagnoses
for patients that are sputum-smear negative require
consensus from at least 2 clinicians. KS diagnoses are
based on clinical examination for oral lesions and
skin biopsy for skin lesions. Skin biopsies are followed
by off-site histopathological examination [20]. Diagnoses
for cryptococcosis are based on serum cryptococcal anti-
gen (CRAG), cerebrospinal fluid (CSF) CRAG, and CSF
India ink tests [21] (although these tests are done only for
patients with symptoms suggestive of chronic meningeal
irritation). Diagnoses of esophagitis, HIV-associated de-
mentia, and weight loss are based on clinical reports.
Laboratory measurements included complete blood
count (CBC) characteristics (hemoglobin concentration,
neutrophil counts, total lymphocyte counts (TLC), eo-
sinophil counts, and platelet counts) and CD4+ T cell
counts (Coulter AC five-part differential, and Coulter
Epics Cytometer, Beckman Coulter, Brea, California) mea-
sured at ART initiation (±3 months). We did not assess
other laboratory parameters, such as, the plasma HIV
RNA levels and liver or kidney function tests, because
these measurements were rarely performed on patients.
Antiretroviral therapy regimens
Data on the patients’ initial ART regimens were also ob-
tained. At this clinic an initial ART regimen contains at
least 3 antiretroviral drugs; a backbone drug, usually a nu-
cleoside- or nucleotide-analog reverse transcriptase inhibi-
tor (NRTI), which can be zidovudine (AZT) (the most
common), tenofovir (TDF), or stavudine (D4T); a second
drug also often a NRTI, which can be either lamivudine
(3TC) or emtricitabine (FTC); and a third drug, usually ei-
ther a non-nucleoside reverse transcriptase inhibitor
(NNRTI) in the form of nevirapine (NVP) or Efavirenz
(EFV), or a protease inhibitor (PI) (although the PIs are
only very rarely used in initial regimens). For example, a
common initial regimen would be a combination of AZT,
3TC, and NVP. We obtained data on the specific regimen
that each patient received. However, as previous studies
suggest that outcomes may vary according to the backbone
drug received (e.g., AZT versus TDF) [22], we assessed
whether the initial ART regimen may have predicted out-
comes by backbone drug received. Consequently, we di-
vided the sample into: those initially receiving AZT-based
regimens (alongside either 3TC or FTC and either EFV or
NVP); those initially receiving TDF-based regimens (with
similar options for the 2nd and 3rd drugs); and those ini-
tially receiving D4T-based regimens (this backbone is re-
cently only rarely used, but also has similar options as the
others for the 2nd and 3rd drugs).
Follow-up and outcomes
Time zero was the date of ART initiation and patients
were followed until death, transfer-out to another service
provider, loss to follow-up, or administrative censoring
on 31 December 2012. The primary outcome was drop-
out from treatment, a composite of death and loss to
follow-up (due to high rates of loss to follow-up in this
setting, assessing either outcome alone may potentially
lead to biased conclusions; hence we decided to assess
both outcomes together as overall “dropout from care”).
Participants were considered to be lost to follow-up if
their last clinic visit was more than 180 days earlier than
the date of administrative censoring in those not trans-
ferred out and not known to have died. The 180-day
period is based on previous studies defining loss to
follow-up in this way [16, 23]. Death was determined
through reports by clinic staff, relatives, peers, or friends,
since Uganda does not have a national death registry.
Clinic staff usually perform limited tracking of patients
who dropout from the clinic by inquiring from relatives,
peers, and friends, who usually would know if a patient
died. Also, patients are at times transferred to other ser-
vice providers; clinic staff usually document this transfer
on the patient’s record (with the information later being
captured by the electronic record). In this analysis, such
patients were censored at the time of transfer.
For purposes of this analysis, we assumed that death
and loss to follow-up were the bad outcomes (hence
these were combined), while transfer to another service
provider or being retained in care were the good out-
comes (these were also combined); our binary outcome
of dropout from care thus compares patients who either
died or were lost to follow-up to those who were either
retained at this clinic or were transferred officially to an-
other provider.
Analysis
We first performed descriptive analyses on the full sam-
ple to assess the degree of missing data and to describe
outcomes. We then performed multiple imputations of
missing data (as described below) before using propor-
tional hazards regression to assess predictors of dropout.
In unadjusted analyses, we assessed all available
sociodemographic, clinical, and laboratory variables.
CBC parameters and age were modelled in quartiles;
CD4+ T cell count was categorized in clinically-
relevant fashion: <100, 100–199, 200–349, and ≥350
cells/μL.
We set up the analysis so that, for each variable,
the reference category was that, which we hypothe-
sized pre-analysis to have the lowest risk of dropout.
For example, based on some previous studies [24,
25], we hypothesized that older patients on ART are
less likely to dropout than younger patients, the
married are less likely to dropout than the single,
those with higher hemoglobin or higher CD4+ T cell
concentrations are less likely to dropout than those
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with lower concentrations, etc. Consequently, these
“normal values” categories were used as the reference
per variable. In similar fashion, for variables such as
the total lymphocyte counts or the platelet counts,
our reference groups were the middle-of-the-range
values; we suspected that patients with either re-
duced or elevated levels of these cell types (i.e., pa-
tients with “abnormal” values) would have higher
risk of dropout. We then used proportional hazards re-
gression to calculate the hazard ratio (HR) of dropout per
variable comparing patients in the other categories to
those in the reference category and assessed associated P
values. The HR in this case is interpretable as a ratio of
the instantaneous risk of dropout among patients in a
given category versus those in the reference category.
To determine independent predictors of dropout, we
included variables that had P values <0.1 in unadjusted
analyses in a multivariable proportional hazards regres-
sion model predicting dropout. Using a stepwise back-
ward selection procedure, we removed variables from
the model until only those that were statistically signifi-
cantly associated with dropout at P <0.05 remained. As
previous studies among HIV infected patients in this set-
ting suggest that calendar time may be associated with
death, loss to follow-up, and the quality of data collected
from patients [26, 27], we also included the year of ART
initiation in the adjusted analysis.
In addition to the main analysis above, which evalu-
ated the patients’ individual-level characteristics as pre-
dictors of dropout, we evaluated whether initial ART
regimens (based on the backbone drug received) pre-
dicted risk of dropout. As some previous studies suggest
that TDF- or D4T-based regimens may be more associ-
ated with negative outcomes than AZT-based regimens
[22, 28], we compared risk of dropout in patients receiv-
ing AZT-based regimens (as the reference) to dropout
risk in those receiving either TDF-based or D4T-based
regimens. In this analysis, we suspected that, at a mini-
mum, sex, age, and year of ART initiation, would be
confounders of associations between initial regimen and
dropout. Additionally, we suspected that clinicians might
be less inclined to give AZT to patients that present with
low hemoglobin concentrations, and in one previous
study, patients with more advanced HIV disease stage at
ART initiation, were more likely to be treated with TDF-
based regimens [29], yet such patients may also be likely
to dropout. Consequently, we assessed the association
between initial ART regimen and risk of dropout, adjust-
ing for age, sex, year of ART initiation, and the CD4+ T
cell count and hemoglobin concentrations at ART initi-
ation, as the minimum sufficient adjustment set of
confounders.
Between 14 and 41 % of patients were lacking data on
at least one of the laboratory-measured predictors. As
missing information could potentially bias our conclu-
sions [30], we assessed whether missing data on any
variable was associated with dropout. We then multiply
imputed missing predictor values, using variables with
complete information (age, sex, OI/comorbidity diagno-
ses, dropout status, and follow-up time), as well as the
available data from the variables with missing values
[31]. Categorical variables were imputed using multi-
nomial logistic regression with the “augment” option to
prevent perfect prediction [32]; numeric variables were
imputed using predictive mean matching since they had
skewed distributions [33, 34]; binary variables were
imputed using logit models. Imputation procedures used
iterative chained equations with 40 repetitions [35].
Analyses were performed in Stata 13 (Stata Corp,
College Station, Texas, USA).
Results
Overall sample characteristics
Between January 2008 and December 2011, a total of
5,057 HIV-infected patients (64 % female) initiated ART.
The median age was 33 years (IQR 28 to 40); 27.4 % had
CD4+ T-cell counts <100 cells/μL (Table 1). Median
follow-up was 24 months (IQR = 14 to 42, maximum
follow-up = 64 months). Overall dropout was 26.9 %
(established cumulative mortality = 2.3 %, loss to follow-
up = 24.6 %), 5.6 % were transferred to other service pro-
viders, and 67.5 % were retained in care. The risk of
dropout was not substantially different between those
with data versus those without data on the variables that
had missing data (Table 2).
Initial ART regimens
The majority of patients were initially treated with AZT-
based regimens (for 58.5 % of the cohort, AZT was given
alongside 3TC and NVP, and for 15.1 % AZT was given
alongside 3TC and EFV). TDF-based regimens were ini-
tially given to 22.3 % overall (for 19.5 % TDF was com-
bined with either 3TC or FTC and EFV and for 2.9 %
NVP was used as the third drug). A small percent
(4.1 %) received D4T-based regimens (with either 3TC
and NVP or 3TC and EFV).
Predictors of dropout from care
In the unadjusted analysis to evaluate predictors of drop-
out among those variables that are routinely collected
from patients at ART initiation, we assessed 20 variables
(shown in Table 1). Fifteen variables: sex, age, marital
status, history of cryptococcosis, KS diagnosis, (recent)
history of TB, weight loss ≥10 %, oral candidiasis,
chronic diarrhea, HIV associated dementia, CD4+ T-cell
count, hemoglobin concentration, platelet count, total
lymphocyte count, and year of ART initiation predicted
dropout at P <0.1. These were included in the
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multivariable adjusted proportional hazards regression
model. Using a step-wise backward selection procedure,
we removed variables from the model until 12 variables,
all of which predicted dropout at P <0.05, remained
(Table 3).
A diagnosis of KS (HR = 3.3, 95 % CI 2.5 to 4.5);
HIV-associated dementia (HR = 2.6, 95 % CI 1.5 to
4.6); history of cryptococcosis (HR = 2.2, 95 % CI 1.4
to 3.3); and reduced hemoglobin concentration
(<11 g/dl versus ≥13.8 g/dl (HR = 1.9, 95 % CI 1.6 to
2.2) were strong predictors of dropout. Other inde-
pendent predictors of dropout were: year of ART initi-
ation; weight loss ≥10 %; reduced total lymphocyte count;
chronic diarrhea; male sex; young age (≤28 years); and
marital status (Table 3).
Initial ART regimens and risk of dropout
In the unadjusted analysis, compared to those initially
receiving AZT-based regimens, those receiving either
TDF- or D4T-based regimens appeared to have a higher
risk of dropout from treatment. After adjusting for age,
Table 1 Characteristics of 5,057 patients who were analyzed in the
study. The patients initiated ART in 2008 to 2011 at the Immune
Suppression Syndrome Clinic in Mbarara, Uganda
Variable
Age 33 (28–40)a
Sex, Female 63.9 %
Education
No education 5.5 %
Primary 62.1 %
Secondary or more 32.5 %
Time to clinic
≤1 h 14.8 %
1-2 h 20.4 %
2-3 h 21.9 %













Tuberculosis, history of 5.9 %
Kaposi’s sarcoma diagnosis 1.6 %
Cryptococcosis, history of 1.2 %
Esophagitis 2.2 %
Oral candidiasis 17.2 %
Chronic diarrhea 11.3 %
Weight loss ≥10 % 12.9 %
HIV-associated dementia 0.57 %
CD4+ T-cell counts (cells/μL)
< 100 27.4 %
100–200 25.9 %
200–349 36.6 %
≥ 350 10.1 %
Hemoglobin (g/dl) 12.3 (11.0–13.7)
Neutrophils (x 103 cells/μL) 1.7 (1.1–2.4)
Eosinophils (x 103 cells/μL) 0.09 (0.04–0.20)
Platelets (x 103 cells/μL) 208 (155–268)
Lymphocytes (x 103 cells/μL)b 1.6 (1.1–2.0)
Table 1 Characteristics of 5,057 patients who were analyzed in the
study. The patients initiated ART in 2008 to 2011 at the Immune
Suppression Syndrome Clinic in Mbarara, Uganda (Continued)
Initial ART regimens
AZT, 3TC, NVP 58.5 %
AZT, 3TC, EFV 15.1 %
TDF, 3TC/FTC, EFV 19.4 %
TDF, 3TC/FTC, NVP 2.9 %
D4T, 3TC, EFV/NVP 4.1 %
AZT zidovudine, 3TC lamivudine, D4T stavudine, NVP nevirapine, EFV efavirenz,
TDF tenofovir
aMedian (Interquartile range) unless otherwise specified
bTotal lymphocyte count (TLC)
Table 2 Proportions with missing data and risk of dropout per
variable for variables with missing data. The table shows the
proportion of patients dropping out among those with data
versus those without data in the full sample (N = 5,052) per
variable for those variables which had some missing data
Variable Missing
data (%)
Dropout risk in those
with data (%)
Dropout risk in those
without data (%)
Education 31.1 18.8 17.2
Marital status 14.8 18.3 18.2
Time to clinic 29.3 19.4 15.5
CD4+ T cell count 21.2 17.8 20.0
Hemoglobin 28.2 18.3 18.3
Eosinophils 40.7 17.9 18.9
Neutrophils 33.5 18.3 18.2
Platelets 28.5 18.2 18.4
Total lymphocytes 32.5 18.3 18.2
Asiimwe et al. BMC Infectious Diseases  (2016) 16:43 Page 5 of 10
Table 3 Hazard ratios of dropout per variables for variables that predicted dropout
Unadjusted analysis Adjusted analysis
Variable HR (95 % CI) P AHRa (95 % CI) P
Age
16–28 1.3 (1.2–1.5) <0.001 1.4 (1.2–1.6) 0.001
29–33 0.97 (0.83–1.1) 0.722 1.0 (0.685–1.2) 0.916
34–40 0.98 (0.84–1.1) 0.769 0.95 (0.80–1.1) 0.573
41–83 Ref. Ref Ref. -
Sex
Female Ref. Ref. -
Male 1.2 (1.1–1.4) <0.001 1.4 (1.2–1.6) <0.001
Marital status
Separated 1.4 (1.2–1.7) <0.001 1.3 (1.1–1.5) 0.007
Divorced 1.4 (1.1–1.8) 0.005 1.3 (1.1–1.7) 0.017
Widowed 1.2 (0.90–1.3) 0.515 1.1 (0.88–1.3) 0.561
Single 1.6 (1.3–1.9) <0.001 1.3 (1.1–1.6) 0.012
Married Ref. - Ref. -
Year of ART initiation
2008 1.8 (1.5–2.0) <0.001 1.6 (1.4–1.9) <0.001
2009 1.6 (1.4–1.9) <0.001 1.4 (1.2–1.7) <0.001
2010 1.2 (1.0–1.5) 0.025 1.0 (0.82–1.2) 0.963
2011 Ref. - Ref. -
Tuberculosis, history of 1.6 (1.4–2.0) <0.001 1.4 (1.2–1.7) <0.001
Kaposi’s sarcoma 4.3 (3.3–5.7) <0.001 3.3 (2.5–4.5) <0.001
Cryptococcosis, history of 2.4 (1.7–3.4) <0.001 2.2 (1.4–3.3) <0.001
Oral candidiasis 1.3 (1.1–1.5) <0.001 - -
Chronic diarrhea 1.3 (1.2–1.6) <0.001 1.3 (1.1–1.5) 0.008
Weight loss ≥10 % 1.8 (1.6–2.1) <0.001 1.5 (1.2–1.8) <0.001
HIV-associated dementia 2.0 (1.2–12.8) 0.008 2.6 (1.5–4.6) 0.001
CD4+ T cell count
<100 (cells/μL) 1.9 (1.5–2.4) <0.001 - -
100-199 1.2 (0.96–1.5) 0.107 - -
200-349 1.0 (0.83–1.3) 0.768 - -
≥350 Ref. - - -
Hemoglobin concentration
≤11.0 (g/dl) 2.0 (1.7–2.4) <0.001 1.9 (1.6–2.2) <0.001
11.1–12.4 1.4 (1.2–1.6) <0.001 1.4 (1.1–1.6) 0.002
12.5–13.7 1.1 (0.91–1.3) 0.411 1.1 (0.94–1.4) 0.171
≥13.8 Ref. - Ref. -
Platelet counts
≤155 (cells/μL) 1.2 (1.0–1.4) 0.017 - -
156–208 0.99 (0.84–1.2) 0.865 - -
209–267 Ref. - - -
268–720 1.1 (0.93–1.3) 0.301 - -
Total lymphocyte count
≤1.12 (x 103 cells/μL) 1.6 (1.4–1.9) <0.001 1.4 (1.2–1.7) <0.001
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sex, year of ART initiation, and the CD4+ T cell count
and hemoglobin concentration at ART initiation, those
initially receiving TDF-based regimens had a 1.4-fold
higher risk of dropout (95 % CI 1.2 to 1.7) than those
initially receiving AZT-based regimens. Those initially
receiving D4T-based regimens had a 1.2-fold higher risk
of dropout but the result was not statistically significant
(95 % CI 0.92 to 1.5) (Table 4).
Discussion
In SSA, HIV-infected patients commonly drop out from
treatment after initiating ART; the majority of dropouts
are lost to follow-up [12]. This problem complicates the
evaluation of HIV treatment services [36, 37], and inter-
ventions are needed to improve not only individual-level
patient outcomes, but also outcome ascertainment. In
this study, we assessed predictors of dropout from care
among HIV-infected patients initiating ART at a public
sector HIV treatment clinic in Uganda. Our data suggest
that a number of variables that are routinely collected at
ART initiation can predict dropout.
Correlates of death in HIV-infected patients such as
cryptococcosis [38, 39] and a diagnosis of KS [40], as
well as other proxies of HIV-disease progression at ART
initiation, including reduced hemoglobin concentration
and weight loss, [41] were especially predictive of drop-
out from care. As majority of dropouts in our analysis
were lost to follow-up, we interpret these results to
mean that many of the patients who got lost to follow-
up are likely to have died.
This observation is consistent with observations from
other programs and studies in the region. In a recent
study in Ethiopia, predictors of attrition included severe
immune deficiency at enrollment, a functional status of
“bed-ridden” or “ambulatory”, compared to “working”,
and male sex [42]. In another study in Zimbabwe, ad-
vanced HIV disease stage, and lower body weight at
ART initiation also predicted attrition [43]. In a study
which tracked a sample of those lost to follow-up, cu-
mulative mortality among those lost to follow-up was
36 % at one year suggesting a high risk of death in those
lost to follow-up [16].
Our observations would therefore suggest that earlier
initiation of ART, before excessive HIV disease progres-
sion has occurred, may be one way to improve both
individual-level patient outcomes, as well as outcome as-
certainment in this setting [44]. We were unable to sep-
arately identify predictors of loss to follow-up from
predictors of death (due to high rates of loss to follow-
up in a context of inadequate ascertainment of death
status). However, consistent with our observations, some
previous studies suggest that young age, male sex, and
marital status, as well as advanced HIV disease stage,
predict loss to follow-up among ART initiators [24, 25].
Potentially, intensive follow-up for patients initiating
ART may improve outcome ascertainment. For example,
in research programs, where patients usually get inten-
sively tracked, rates of loss to follow-up tend to be low
(8 % at 3 years in one report) [45]. In contrast, in routine
treatment programs, rates of loss to follow-up are high
(e.g., 39 % at 3 years in a sample of all HIV-infected pa-
tients [16], and 30.8 % at 8 months in a sample of those
co-infected with TB and HIV [17]). However, as in-
tensively tracking all patients in a routine treatment
program may be difficult, a better understanding of
predictors of dropout could guide the development of
predictive models that can be used to target interven-
tions like intensive follow-up. In routine treatment
programs, such models could be more useful if they
predict both death and loss to follow-up as both are
common negative outcomes in the context of ART in
this setting.
Other interventions that can improve individual-level
patient outcomes should also be investigated. For ex-
ample, it may be that those dropping out require treat-
ments over and above ART, which are not being
provided in the present era. As some previous studies
suggest that the immune reconstitution syndrome (IRIS)
may lead to early death in some patients, especially
those with cryptococcal disease [46] or KS [40], the role
Table 3 Hazard ratios of dropout per variables for variables that predicted dropout (Continued)
1.13–1.6 1.3 (1.1–1.5) 0.003 1.2 (1.0–1.4) 0.048
1.61–2.0 Ref. - Ref. -
≥2.01 1.3 (1.1–1.5) 0.001 1.1 (0.94–1.4) 0.171
HR hazard ratio, AHR adjusted hazard ratio, CI confidence interval
aFor the variables that remained in the final adjusted model
Table 4 Initial ART regimens and risk of dropout
Unadjusted analysis Adjusted analysisb
Regimen backbonea HR P AHR P
AZT-based (reference) - - - -
TDF-based 1.2 (1.0–1.4) 0.022 1.4 (1.2–1.7) <0.001
D4T-based‡ 1.3 (0.98–1.6) 0.072 1.2 (0.92–1.5) 0.180
aAZT-based regimens contain zidovudine (AZT), lamivudine (3TC), and either
nevirapine (NVP) or efavirenz (EFV); TDF-based regimens contain tenofovir
(TDF), 3TC or FTC, and either NVP or EFV; D4T-based regimens contain stavudine
(D4T), 3TC, and either NVP or EFV
bAdjusted for age, sex, year of ART initiation, and CD4+ T-cell count and
hemoglobin concentration at ART initiation
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of IRIS and other risk factors for early death after ART
initiation should be further investigated. This may aid
the development of appropriate adjunctive interventions
(i.e., other treatments over and above ART that might im-
prove the survival of some HIV-infected ART initiators).
Other than the patients’ individual-level characteris-
tics, some ART regimens also might conceivably in-
crease risk of dropout. In a previous study which
compared TDF-based regimens to AZT-based regi-
mens, patients receiving a TDF-based regimen as ini-
tial therapy had an about 1.5-fold higher risk of death
at or after 90 days from ART initiation, adjusting for
age, sex, CD4+ cell count, HIV disease stage, body
mass index, hemoglobin concentration, and serum
creatinine at ART initiation [22]. In our data, we also
found that patients on TDF-based regimens had a
1.4-fold higher risk of dropout than those on AZT-
based regimens, although we were not able to adjust
for any differences in baseline kidney function given
that serum creatinine or other related data were not
available. As a strength, our results were adjusted for
all of age, sex, year of ART initiation, and CD4+ T
cell count and hemoglobin concentration at ART ini-
tiation. In another previous study, D4T-based regi-
mens were associated with a higher risk of
symptomatic neuropathy than AZT-based regimens
[28]. In our data, patients initially receiving D4T-
based regimens had slightly increased risk of dropout,
but their number was generally small and the result
was not statistically significant; use of D4T in initial
regimens at this clinic (and in Uganda generally [29])
has recently become rare.
A general limitation of our study is missing data.
For example, if CBCs were not requested for patients
that looked healthy; such patients may also be less
likely to dropout, and the associations of CBC charac-
teristics with dropout may be overestimated [30].
However, those with data were not substantially more
likely to dropout than those without the data, and we
used multiple imputation to impute values for the
missing data. An additional limitation is that we were
only able to assess a relatively small number of vari-
ables that were available in the clinic data; future
studies assessing more variables are needed. Also, our
findings are generally applicable to only routine treat-
ment programs, where more complex variables that
might be more predictive of outcomes tend to be
unavailable.
Conclusions
Among HIV infected patients initiating ART at a public
sector clinic in SSA, several routinely collected variables
predicted risk of dropout from treatment. Biological fac-
tors which usually predict death were especially
predictive of dropout. As the majority of those dropping
out in our study were lost to follow-up, our findings sug-
gest that many of those getting lost to follow-up may
have died. More studies are needed to identify appropri-
ate interventions to improve individual-level patient out-
comes, as well as outcome ascertainment, for HIV-
infected patients initiating ART in this setting.
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